White House Drug Strategy Faces Criticism Over Contradictory Policies on Cannabis and Addiction Care

The White House unveiled its comprehensive 195-page National Drug Control Strategy on May 4, outlining ambitious goals to tackle America's enduring drug and addiction crisis. The plan emphasizes making addiction treatment more accessible than illegal drugs, boosting prevention efforts, supporting recovery, and reducing overdose deaths. While the strategy's broad public health aims are widely lauded by experts, many warn that the administration's own policy decisions could undercut progress. "The administration, on the one hand, is moving in a direction of liberalizing access to cannabis, but at the same time, in the strategy, it talks about the dangers of doing so," said Libby Jones, overdose prevention lead at the Global Health Advocacy Incubator

Critics point to a series of federal actions that conflict with the strategy's stated objectives, such as mass layoffs of public health staff, abrupt cancellations of addiction-related grants, and proposed Medicaid cuts. These moves have destabilized the sector and raised questions about the administration's commitment to its own roadmap. Yngvild Olsen, a national adviser with Manatt Health, described the situation as "whiplash," noting that the field is left with "a sense of instability and uncertainty." The president's 2027 budget request, which seeks to consolidate key agencies and slash funding for addiction and mental health programs, has prompted nearly 100 organizations to urge Congress to reject the proposals

A major pillar of the strategy is increasing access to substance use treatment, an urgent need given that over 80% of Americans requiring care do not receive it. However, the plan's effectiveness is undercut by Medicaid changes projected to strip coverage from 1.6 million people with substance use disorders. Past Medicaid rollbacks have already led to reductions in opioid addiction treatment, and one analysis predicts upcoming changes could result in 156,000 losing access to medications and more than 1,000 additional overdose deaths annually. The administration has also declined to enforce mental health parity regulations, raising concerns that private insurance will not adequately cover addiction treatment

The document's prevention focus is similarly complicated by proposed budget cuts and staff reductions. The strategy calls for science-backed school and community programs and a "drug-free America as the social norm," but the White House's own budget would cut $220 million from prevention initiatives and $40 million from the Drug-Free Communities program. Staff losses at the Substance Abuse and Mental Health Services Administration and the Centers for Disease Control and Prevention further limit the ability to implement prevention measures. "It’s not clear to me that they’re really going to be able to have the funds or the people to be able to carry that out," Olsen said

Marijuana policy stands out as a particular area of contradiction. The strategy warns of cannabis use as a driver of addiction and psychosis risk, yet the administration has recently moved to reclassify medical marijuana to a lower schedule and is considering broader rescheduling. "There’s a disconnect there that just makes you question: Which one do you believe?" Jones observed. The document also supports the legalization of fentanyl test strips for overdose prevention, but recent federal actions have pulled funding from such harm reduction tools, signaling a retreat from policies that facilitate safer drug use

From the OG Lab newsroom perspective, the conflicting signals from the White House's drug strategy and its actual policy decisions create uncertainty for the cannabis and addiction treatment sectors. This development is worth watching as it may influence federal funding, regulatory clarity, and the direction of harm reduction efforts nationwide. The industry will need to monitor how these inconsistencies are resolved—and whether stated public health goals translate into meaningful support for evidence-based interventions